eribulin
1 clinical trial
1 product
31 abstracts
1 indication
1 target
Indication
Breast CancerTarget
TubulinAbstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).Org: Kanagawa Cancer Center, Fukushima Medical University, School of Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), National Cancer Center Hospital East, Kashiwa, Japan, Department of Breast Surgery, Shizuoka General Hospital,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, Jiangsu Province Hospital, Nanjing, China, Hunan Cancer Hospital, Changsha, China, Shandong Cancer Hospital and Institute, Jinan, China, Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.Org: Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Hospital Universitario Ramón y Cajal,
Abstract
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.Org: The University of Texas HSC at San Antonio Cancer Therapy and Research Center,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP).Org: Fukui University School of Medicine,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study.Org: The Cancer Center of the Fifth Affiliated Hospital, The First People's Hospital of Zhaoqing, Jiangmen Central Hospital, Zhuhai Maternity and Child Health Hospital, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine,
Abstract
Efficacy and safety of eribulin-based chemotherapy in patients with advanced breast cancer: A single-centre retrospective study.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study.Org: Fujian Normal University, Department of Breast Oncology, Fujian Cancer Hospital, Department of Oncology, Fujian Medical University Union Hospital, Department of Breast Medical Oncology, Fujian Cancer Hospital, Fuzhou University,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
Clinical outcomes of patients with HR-positive advanced breast cancer treated with eribulin: A retrospective multicenter study from China.Org: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China, Cancer Center of First Hospital of Jilin University, Changchun, China, Department of Medical Oncology, Liaoning Provincial People's Hospital, Shenyang, China,
Abstract
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.Org: Chengdu Shang Jin Nan Fu Hospital,
Abstract
Eribulin and irinotecan for refractory or recurrent Ewing sarcoma: A retrospective study.Org: Peking University People’s Hospital, Beijing, China,
Clinical trial
DETECT V / CHEVENDO A Multicenter, Randomized Phase III Study to Compare Chemo- Versus Endocrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) Plus Kisqali® (Ribociclib) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer.Status: Active (not recruiting), Estimated PCD: 2025-01-31
Abstract
The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).Org: Xilis, Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Xilis, Inc., Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.Org: Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
Clinical implications of recurring mutations in myxoid liposarcoma (MLS).Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Efficacy and safety of eribulin as a front-line treatment in patients with advanced breast cancer: The first large scale prospective real-world study in China.Org: Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, First Affiliated Hospital of Xi’an Jiaotong University,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03.Org: Kanagawa Cancer Center, Matsuyama Red Cross Hospital, Nagoya University Graduate School of Medicine, Asahikawa Medical University Hospital, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study.Org: The Fifth Affiliated Hospital of Sun Yet-Sen University, Zhuhai, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine, Zhuhai, China, Department of Breast Surgery, Zhuhai Maternity and Child Health Hospital, Zhuhai, China, The First People's Hospital of Zhaoqing, Zhaoqing, China,
Abstract
Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China.Org: West China Hospital, Sichuan University, Breast Disease Center, West China Hospital, Sichuan University, West China Hospital of Sichuan University,
Abstract
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,
Abstract
Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers.Org: Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Eisai, Exton, School of Clinical Sciences at Monash Health,
Abstract
Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, CHU Besançon, Besançon, Department of medical onclogy, Peking Union Medical College Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,